Clinical trials: Motor Neuron Disorder
Amyotrophic Lateral Sclerosis
Dexpramipexole SAD/MAD Study
This Phase 1 study will explore the safety, tolerability, and pharmacokinetics of single doses ranging from 300 to 600 mg and multiple daily doses ranging from 225 mg to 300 mg BID dexpramipexole in healthy volunteers.
- Trial name
- NCT01449578
- Testing
- Dexpramipexole
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Knopp Biosciences
Spinal Muscular Atrophy
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) Given by Mouth in Healthy Volunteers
The objective of this study is to assess the safety and tolerability of Risdiplam (RO7034067) in healthy people. The study will assess what the body does to Risdiplam (RO7034067) and what Risdiplam (RO7034067) does to the body.
- Trial name
- NCT02633709
- Testing
- Itraconazole, Risdiplam
- Where
- Netherlands
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Amyotrophic Lateral Sclerosis
Relationship Between Neurological Disability and Visual Impairment in Patients With ALS or Friedreich's Ataxia
The aim of this study is to obtain an early biomarker of amyotrophic lateral sclerosis and Friedreich's Ataxia which allows to diagnose the disease in an initial stage and to follow up the patient with optic coherence tomography…
- Trial name
- NCT03285204
- Where
- Spain
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Jose Luis Urcelay Segura
Amyotrophic Lateral Sclerosis (Healthy Volunteers)
Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants
This is a Phase 1, single-center study conducted in 2 parts: Part 1a, single ascending dose (SAD-TDU16519): Double-blind, randomized, placebo-controlled sequential ascending single oral doses including up to 6 cohorts.
- Trial name
- NCT05795907
- Testing
- SAR443820
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Sanofi
Neuromuscular Disease, Motor Neuron Disease
Electrical Impedance Myography: Natural History Studies inNeuromuscular Disorders and Healthy Volunteers
Background: Electrical impedance myography (EIM) is a new technique being studied to see if it is helpful in evaluating muscle disorders and nerve disorders.
- Conditions
- Neuromuscular Disease, Motor Neuron Disease, Inherited Neuromuscular Conditions, Inherited Neuropathies
- Trial name
- NCT01900132
- Testing
- EIM testing, Nerve & muscle ultrasonography, Nerve conduction studies
- Where
- United States
- Volunteers
- 275 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Amyotrophic Lateral Sclerosis
Evaluating Verbal Communication in Structured Interactions: Theoretical and Clinical Implications
The goal of this clinical trial is to learn about the effect of communicative interaction on verbal communication in people with amyotrophic lateral sclerosis (ALS) and age-matched speakers.
- Trial name
- NCT06266403
- Testing
- Structured Communicative Interaction, Clear Speech, Unstructured communicative interaction
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Penn State University
Amyotrophic Lateral Sclerosis (Healthy Volunteers)
A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)
Part 1: This is an open label, balanced randomized, single dose, 2-sequence, 2-period (period 1 and period 2), 2-treatment crossover (between Treatment A and Treatment B for Part 1), study part to determine the relative…
- Trial name
- NCT05797701
- Testing
- SAR443820
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Sanofi
Amyotrophic Lateral Sclerosis, ENGRAILED1
Identifying Biomarkers in ALS Patients Using Neuronal Derived Extracellular Vesicles
Rationale. ENGRAILED1 (EN1) is under consideration as a therapeutic approach for amyotrophic lateral sclerosis (ALS). To assess EN1 target engagement in patients, we aim to identify EN1-responsive biomarkers suitable as…
- Trial name
- BALNEV (NCT07334743)
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Gait Patterns in Dual-task Conditions in Patients With Amyotrophic Lateral Sclerosis
The investigators hypothesize a relevant impact of cognitive status over gait performance in patients with amyotrophic lateral sclerosis (ALS), contributing to poor mobility and representing a relevant risk for falls.
- Trial name
- NCT06541873
- Testing
- Clinical and gait evaluation
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Multiple Sclerosis, Stroke
An Assistive Powered Wheelchair: Stage 2 Trial
Preliminary evaluation of an obstacle alerting system to enhance the user's independent mobility by improving their confidence to drive and their safety in driving a powered wheelchair.
- Conditions
- Multiple Sclerosis, Stroke, Cystic Fibrosis, Motor Neurone Disease
- Trial name
- EDUCAT (NCT05292690)
- Testing
- Powered Wheelchair Obstacle Alerting System
- Where
- United Kingdom
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- East Kent Hospitals University NHS Foundation Trust
Amyotrophic Lateral Sclerosis
Quantitative Neuromuscular Ultrasonography in Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS) is a progressive and fatal neurological disease. Nonspecific symptoms lead to a delay in the diagnosis, only confirmed by the electrophysiologic study. Objectives. 1.
- Trial name
- ALS (NCT02507713)
- Where
- Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Universidad Católica San Antonio de Murcia
Spinal Muscular Atrophy
A Registered Cohort Study on SMA
Spinal muscular atrophy (SMA) is an autosomal recessive disease that causes progressive muscle wasting and weakness due to loss of motor neurons in the spinal cord.
- Trial name
- NCT04010604
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Wan-Jin Chen
Frontotemporal Dementia, Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Amyotrophic lateral sclerosis (ALS) with frontotemporal dementia (FTD) is a rare clinical entity, in which both disorders are variably associated in the same patient or within the family.
- Trial name
- NCT00159198
- Where
- 15 sites in France
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Amyotrophic Lateral Sclerosis
LONgitudinal and Integrated Evaluation of Biomarkers in reLation to phenotYpe in ALS
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive degeneration of upper and lower motor neurons, leading to paralysis and death.
- Trial name
- LONELYALS (NCT07312240)
- Testing
- Lumbar Puncture for analysis of Cerebrospinal Fluid, Deep Phenotyping, Routine blood chemistry analysis and genetic analysis
- Where
- Italy
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Istituto Auxologico Italiano
Spinal Muscular Atrophy, Neuromuscular Disease
Clinical Trial of Exercise in Patients With Spinal Muscular Atrophy (SMA)
This study is being conducted to test whether exercise can be effectively used as an intervention to treat Spinal Muscular Atrophy (SMA).
- Trial name
- NCT01166022
- Testing
- Exercise
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Columbia University
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
EEG and TMS-based Biomarkers of ALS, MS and FTD
The purpose of this observational study is to improve understanding of the biology of why ALS, MS and FTD have different effects on different people and facilitate better measurement of the disease in future drug testing.
- Conditions
- Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Multiple Sclerosis
- Trial name
- NCT04918251
- Testing
- 128 electrode electroencephalography (EEG), Transcranial magnetic stimulation (TMS)
- Where
- Ireland
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of Dublin, Trinity College
Pompe Disease (Late-onset), Myotonic Dystrophy Type 1 (DM1)
Musculoskeletal Nociceptive Pain in Participants With Neuromuscular Disorders
The primary aim is to characterize the prevalence, severity and quality of musculoskeletal nociceptive pain in adult patients with neuromuscular disorders (NMD).
- Conditions
- Pompe Disease (Late-onset), Myotonic Dystrophy Type 1 (DM1), Myotonic Dystrophy Type 2, Spinal Muscular Atrophy Type 3
- Trial name
- NCT04907162
- Testing
- Beck depression inventory fast screen, German Pain Inventory, Brief Pain Inventory
- Where
- Germany
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- LMU Klinikum
Muscle Spasticity, Healthy
Physiologic Studies of Spasticity
This study will provide information about changes that occur in the motor neurons of the spinal cord (the nerve cells that control the muscles) when the motor cortex (the region of the brain that controls movement) is unable to…
- Trial name
- NCT00014976
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Dementia, Alzheimer Disease
The Swedish BioFINDER 2 Study
The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g.
- Conditions
- Dementia, Alzheimer Disease, Parkinson Disease, Lewy Body Disease
- Trial name
- BioFINDER2 (NCT03174938)
- Testing
- Flutemetamol F18 Injection, [18F]-RO6958948, Elecsys (Roche) Abeta42, Ttau and Ptau
- Where
- 2 sites in Sweden
- Volunteers
- 2,950 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital
Amyotrophic Lateral Sclerosis (ALS)
Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis
This is a multicenter, 18-month study, which aims to identify imaging and biofluid biomarkers in people with ALS to expand the understanding of ALS pathology, treatment targets, disease progression, and anatomical differences…
- Trial name
- TRACK-ALS (NCT02559869)
- Testing
- [18F] GE-180
- Where
- 2 sites in United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital